

Research Article: New Research / Cognition and Behavior

Phasic Stimulation of Midbrain Dopamine Neuron Activity Reduces Salt Consumption

Eleanor C. Sandhu^{1,2}, Anushka B. P. Fernando^{1,2}, Elaine E. Irvine^{1,2}, Kyoko Tossell^{1,2}, Michelle Kokkinou^{1,2}, Justyna Glegola^{1,2}, Mark A. Smith^{1,2}, Oliver D. Howes^{1,3}, Dominic J. Withers^{1,2} and Mark A. Ungless^{1,2}

¹MRC London Institute of Medical Sciences (LMS), Du Cane Road, London, W12 0NN, UK

²Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, UK

³Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, De Crespigny Park, London, SE5 8AF, UK

DOI: 10.1523/ENEURO.0064-18.2018

Received: 9 February 2018

Revised: 12 March 2018

Accepted: 13 March 2018

Published: 23 April 2018

Author contributions: E.S., A.F., E.I., K.T., O.H., D.W., and M.U. designed research; E.S., A.F., E.I., K.T., M.K., J.G., and M.S. performed research; E.S., A.F., E.I., K.T., and M.U. analyzed data; E.S., A.F., E.I., K.T., O.H., D.W., and M.U. wrote the paper.

Funding: <http://doi.org/10.13039/501100000265>Medical Research Council (MRC)

MC-A654-5QB70

MC-A654-5QB40

MC-A656-5QD30

Conflict of Interest: Authors declare no conflict of interests.

D.J.W. and M.A.U. are co-senior authors.

Corresponding authors: Mark A. Ungless: mark.ungless@imperial.ac.uk or Dominic J. Withers: d.withers@imperial.ac.uk

Cite as: eNeuro 2018; 10.1523/ENEURO.0064-18.2018

Alerts: Sign up at eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process.

Copyright © 2018 Sandhu et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1 **Phasic stimulation of midbrain dopamine neuron activity reduces salt**
2 **consumption**

3

4 Eleanor C. Sandhu^{1,2}, Anushka B. P. Fernando^{1,2}, Elaine E. Irvine^{1,2}, Kyoko
5 Tossell^{1,2}, Michelle Kokkinou^{1,2}, Justyna Glegola^{1,2}, Mark A. Smith^{1,2}, Oliver D.
6 Howes¹⁻³, Dominic J. Withers^{1,2*}, & Mark A. Ungless^{1,2*}

7

8 ¹ MRC London Institute of Medical Sciences (LMS), Du Cane Road, London
9 W12 0NN, UK

10

11 ² Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College
12 London, Du Cane Road, London W12 0NN, UK

13

14 ³ Department of Psychosis Studies, Institute of Psychiatry, Psychology &
15 Neuroscience, Kings College London, De Crespigny Park, London SE5 8AF,
16 UK.

17

18 * co-senior authors

19 Corresponding authors:

20 Mark A. Ungless: mark.ungless@imperial.ac.uk

21 Dominic J. Withers: d.withers@imperial.ac.uk

22

23 Pages: 51, Figures=5. Words: Abstract=155, Introduction=513, Discussion =
24 1491

25 The authors declare no competing financial interests.

26 **Acknowledgements**

27 We thank Eleanor Paul, Rebecca Davis, and Darren Hardy for technical
28 assistance, and Paul Chadderton and Matthew Brown for advice regarding
29 optogenetics. This research was supported by grant MC-A654-5QB70 from
30 the U.K. Medical Research Council and a University Research Fellowship
31 from The Royal Society to M.A.U., grant MC-A654-5QB40 from the UK
32 Medical Research Council to D.J.W. and grant MC-A656-5QD30 from the UK
33 Medical Research Council to O.D.H.. E.C.S. was supported by the National
34 Institute for Health Research (NIHR) Imperial Biomedical Research Centre.
35 The views expressed are those of the author(s) and not necessarily those of
36 the NHS, the NIHR or the Department of Health.

37 **Abstract**

38 Salt intake is an essential dietary requirement, but excessive consumption is
39 implicated in hypertension and associated conditions. Little is known about
40 the neural circuit mechanisms that control motivation to consume salt,
41 although the midbrain dopamine system, which plays a key role in other
42 reward-related behaviours, has been implicated. We, therefore, examined the
43 effects on salt consumption of either optogenetic excitation or chemogenetic
44 inhibition of ventral tegmental area (VTA) dopamine neurons in male mice.
45 Strikingly, optogenetic excitation of dopamine neurons decreased salt intake
46 in a rapid and reversible manner, despite a strong salt appetite. Importantly,
47 optogenetic excitation was not aversive, did not induce hyperactivity, and did
48 not alter salt concentration preferences in a need-free state. In addition, we
49 found that chemogenetic inhibition of dopamine neurons had no effect on salt
50 intake. Lastly, optogenetic excitation of dopamine neurons reduced
51 consumption of sucrose following an overnight fast, suggesting a more
52 general role of VTA dopamine neuron excitation in organising motivated
53 behaviors.

54 **Significance Statement**

55 Although it is well-established that midbrain dopamine neurons are involved in
56 many types of reward-related behaviours, little is known about their role in salt
57 intake under conditions where salt is appetitive (i.e. during salt depletion).
58 Here, we show that optogenetic excitation of midbrain dopamine neurons can
59 decrease salt intake. Importantly, this stimulation protocol did not affect salt
60 concentration preferences. Furthermore, we find that this stimulation protocol
61 can also reduce sucrose intake following an overnight fast, suggesting a
62 broader role for dopamine neuron activity in regulating nutrient intake, which
63 compliments findings from previous lesion- and pharmacological-based
64 studies.

65 **Introduction**

66 Dietary sodium intake is essential to the regulation of fluid and electrolytes
67 within the body. Indeed, chronic salt depletion, through diet or the use of low
68 sodium dialysate during dialysis, has been associated with increased mortality
69 (Alderman & Cohen, 2012). Moreover, in certain patient groups (for example
70 the elderly and during diarrheal illness) the physiological ability to respond to
71 salt depletion is impaired due to medication or illness. This is significant since
72 hyponatremia has profound multi-organ consequences which may be fatal. It
73 is therefore essential to maintain total body salt homeostasis. This is normally
74 achieved through physiological control of loss and intake. Accordingly, a
75 strong sodium appetite occurs in response to low levels of sodium in the body
76 resulting in consumption of high salt foods (Richter, 1956; Denton, 1982).
77 However, excessive salt intake, beyond metabolic need, leads to increased
78 blood pressure and the risk of both cardiovascular disease and obesity (Ma *et*
79 *al.*, 2015). There are major public health initiatives to reduce salt intake (World
80 Action on Salt and Health; <http://www.worldactiononsalt.com>). Despite these,
81 there has been little evidence of a reduction in salt consumption at a
82 population level (McCarron *et al.*, 2013; Asayama *et al.*, 2014). There is,
83 therefore, a pressing need to understand better the mechanisms through
84 which salt consumption is mediated and to develop therapeutic interventions
85 that could regulate intake.

86

87 One useful framework for understanding the neural basis of salt appetite
88 proposes that it is regulated by three distinct neural components (Geerling &
89 Loewy, 2008). First, salt depletion is detected by subfornical organ neurons

90 and nucleus of the solitary tract (NTS) neurons expressing the enzyme 11 β -
91 hydroxysteroid dehydrogenase type 2 (HSD2). These neurons are excited by
92 salt depletion and when stimulated can drive salt appetite (Geerling & Loewy,
93 2008; Jarvie & Palmiter, 2016; Nation *et al.*, 2016). Second, gustatory signals
94 transmit information about the detection of salt via non-HSD2 expressing NTS
95 neurons (Geerling & Loewy, 2008). Third, these two signals are integrated in
96 forebrain sites to drive motivated behaviour to consume salt (Geerling &
97 Loewy, 2008). These forebrain sites include the mesocorticolimbic dopamine
98 system, which plays a key role in processing information about other types of
99 reward Wise, 2006. There is some evidence linking the reinforcing properties
100 of salt intake to the dopamine system. For example, dopamine type 2 receptor
101 (D2R) antagonists reduce sham drinking of sodium chloride (NaCl) where fluid
102 empties through a gastric fistula minimizing post-ingestive inhibitory signals
103 when compared to normal drinking of NaCl (Roitman *et al.*, 1997).
104 Furthermore, salt depletion results in an increase in dopamine release in the
105 nucleus accumbens upon unconditioned presentation of NaCl, which is not
106 seen when the animal is salt replete suggesting salt appetite positively
107 modulates dopamine signalling (Cone *et al.*, 2016). Taken together these
108 findings suggest that during salt appetite, salt becomes appetitive and
109 engages neural circuits (particularly the dopamine system) that are involved in
110 mediating appetitive behaviour towards other types of reward. However, it is
111 not well understood how changes in dopamine neuron activity affect salt
112 intake. Interestingly, excitation of dopamine neurons has recently been shown
113 to suppress sucrose drinking and feeding behaviour (Mikhailova *et al.*, 2016;

114 Boekhoudt *et al.*, 2017). We, therefore, hypothesised that under conditions of
115 salt appetite, excitation of dopamine neurons would suppress salt intake.

116 **Methods**

117 *Animals*

118 Mice were housed in cages of 2-4 animals and maintained on a 12 h light/dark
119 cycle. Prior to any changes in diet, food and water were available *ad libitum*.
120 Male C57BL6 mice, 16-18 weeks, (Charles River, UK; IMSR Cat# CRL:27,
121 RRID:IMSR_CRL:27) were used in non-optogenetic studies. For the
122 optogenetic studies, male DAT-iCre heterozygous mice (DATcre+) and wild-
123 type litter mates (DATcre-) on a C57BL/6 background were used (IMSR Cat#
124 EM:01738, RRID:IMSR_EM:01738; Turiault *et al.*, 2007). Animal husbandry
125 and experimental procedures were undertaken in accordance with the United
126 Kingdom Animal (Scientific Procedures) Act of 1986.

127

128 *Virus*

129 The DIO-ChR2-mCherry construct was kindly gifted by the Deisseroth Lab
130 and the viral particles were produced by Vector Biolab, Philadelphia.
131 Concentrations varied minimally with batches of virus across experiments,
132 they ranged from $2.7\text{--}5.8 \times 10^{13}$ GC/ml but were diluted down to 2.0×10^{12}
133 GC/ml. DREADD (designer receptors exclusively activated by designer drugs)
134 construct of human muscarinic acetylcholine receptor M4 fused to mCherry
135 (hM4Di-mCherry) was constructed according to Nawaratne *et al.*, 2008 and
136 cloned into pAAV-Eifla-DIO-WPRE vectors. DREADD construct of human
137 muscarinic acetylcholine receptor M3 fused to mCherry (hM3Dq-mCherry)
138 was obtained from Prof Graeme Milligan, University of Glasgow, and was
139 inserted into pAAV-Eifla-DIO-WPRE vectors (gift from Deisseroth Lab,
140 Stanford:http://web.stanford.edu/group/dlab/optogenetics/sequence_info.html)

141 . The vectors were packaged in AAV serotype 2/1 vector consisting of the
142 AAV2 ITR genomes and the AAV1 serotype capsid gene, titer 2.1×10^{12}
143 GC/ml.
144 (Vector Biolab, Philadelphia).

145

146 *Surgery*

147 Ten to twelve-week-old mice were anaesthetised with isoflurane (5% for
148 induction; 1-2% for maintenance) and placed into a Kopf stereotaxic frame
149 (Bilaney Consultants, UK). 0.25 % bupivacaine was injected subcutaneously
150 beneath the scalp before an incision was made down the midline. For AAV
151 injections, holes were drilled bilaterally to target the VTA using the
152 coordinates AP -3.45 mm, ML ± 0.4 mm, DV -5.05 mm. For optogenetic
153 stimulation studies, to accommodate implantable fibres a 10-degree angle
154 was used and coordinates were ML ± 1.3 mm, DV -4.89 mm (injection) -4.44
155 mm (optical fibre). 0.5 μ l of AAV was injected, bilaterally into the VTA using a
156 33gauge metal needle and a 5 μ l Hamilton glass syringe at a rate of 0.15
157 μ l/min. The needle was left for 5 min post injection before being slowly
158 removed. Following this, implantable optical fibres (constructed according to
159 Sparta *et al.*, 2011) were placed bilaterally, via the same craniotomies. Two
160 screws were placed dorsal to lambda and anterior to bregma to anchor a
161 dental cement cap. Mice recovered from anaesthesia in a heated chamber,
162 were group housed, and left to recover for at least two weeks prior to handling
163 and habituation. Microscopic inspection, under light anaesthesia, of a test
164 cohort showed no damage to the ferrules by littermates after 2 weeks.

165

166 *Handling and habituation*

167 Mice were handled for 2 weeks, and habituated to the testing jellies and
168 apparatus for 1 week prior to the test session.

169

170 *Induction of appetite*

171 For the salt appetite experiments, an acute sodium depletion protocol was
172 used. Briefly, 2 weeks prior to testing, mice were switched to low sodium diet
173 (RM<0.025%Na, Special Diets Services, Essex UK) with access to NaCl, via
174 a glass dish, containing 0.4 % agar jelly and 0.75 M NaCl in their home cage.
175 Two days prior to the test session, mice were injected intra-peritoneally with
176 furosemide (20 mg/kg) (Hameln Pharmaceuticals), their cages changed and
177 the sodium chloride jellies were replaced with 0.4 % agar jellies. This was
178 repeated for a second day, followed by the test day. Saline controls followed
179 the same protocol but were maintained on normal chow with NaCl jellies
180 throughout and were injected with vehicle (NaCl; 0.9% 2ml/kg) (Animalcare
181 Ltd) for two days prior to the test session. The experimenter was blind to
182 group allocation and setup. A fasted state was achieved with removal of all
183 food at 4 pm prior to the test day, although water remained *ad libitum*. This
184 overnight-fasted state was used in experiments testing sucrose appetite and
185 in the need-free sodium preference experiment.

186

187 *Test procedure*

188 Mice were tethered to the laser via patchcords and placed in their designated
189 testing chamber (base of Allentown XJ cage, 19.37 x 38.13 x 13.03 cm) with a
190 paper liner. Following 10 min of habituation, laser stimulation was started. 5

191 min into the stimulation protocol, three jellies of three different concentrations
192 were placed at one end of the chamber. The order of jellies was
193 systematically randomized and was kept constant throughout habituation and
194 testing for each mouse. Mice were allowed to freely consume the jellies for
195 the 30 min test session. The jellies were removed every 10 min, weighed and
196 then returned to the chamber. For chemogenetic experiments the mice were
197 injected with clozapine-*N*-oxide (CNO: 0.1 mg/kg; i.p.) and placed in their
198 testing chamber. Jellies were placed in the test chamber after 30 min and the
199 test session began.

200

201 *Optical stimulation*

202 For optical stimulation studies, implantable optic fibres were attached to a 1x2
203 intensity division fiber-optic rotary joint (Doric Lenses Inc.) using patch cords
204 (Doric Lenses Inc) via a zirconia sleeve. An insulated optical fibre connected
205 the rotary joint to a 473 nm laser source (CrystaLaser and Vortran Laser
206 Technology Inc.). Light output was adjusted by measuring the light output
207 from the tip of an implantable optical fibre using an optical power meter,
208 aiming for a power of 2-3 mW from the tip of the implanted ferule. A phasic
209 illumination pattern was used in experiments with channelrhodopsin. This
210 consisted of 8 pulses of 5ms pulse width, spaced 37ms apart, every 5s,
211 similar to previously published optogenetic stimulation studies (Adamantidis *et*
212 *al.*, 2011; Tye *et al.*, 2013).

213

214 *Immunohistochemistry*

215 Mice were anaesthetised with Isoflurane (5%) and then 0.08 ml Euthatal 100
216 mg/ml i.p. and perfused transcardially with approximately 30 ml of 0.01 M
217 phosphate buffered saline (PBS) followed by 100ml of PBS containing 4 %
218 paraformaldehyde (4 % PFA) at 4°C. The brain was immediately removed and
219 post fixed in 4 % PFA for 2h. Subsequently the brains were cryoprotected in
220 30% sucrose in PBS, embedded in optimal cutting temperature (OCT)
221 medium and frozen in isopentane at -50°C. Brains were stored at -80°C until
222 they were coronally sectioned at 70 µm on a cryostat (Leica CM1800, Leica
223 Microsystems). Free floating sections were washed 4 times in PBS for 5 min,
224 then incubated with 6% normal donkey serum in 0.2 % Triton X in PBS (PBS-
225 Tx). Sections were then incubated simultaneously with primary antibodies, in
226 2 % normal donkey serum in PBS-Tx, at 4°C as follows: chicken anti-tyrosine
227 hydroxylase (1:1000; Abcam Cat# ab76442, RRID:AB_1524535) for a
228 minimum of 24 h; rabbit anti-cFos (1:20000; Millipore Cat# PC38,
229 RRID:AB_2106755) for a minimum of 74 h. Sections were then washed 4
230 times in PBS-Tx for 5 min and then incubated with the appropriate secondary
231 antibodies: AlexaFluor488 donkey anti-rabbit (1:1000; Thermo Fisher
232 Scientific Cat# R37118, RRID:AB_2556546) and AlexaFluor633 goat anti-
233 chicken (1:1000; Thermo Fisher Scientific Cat# A-21103, RRID:AB_2535756)
234 or 488 goat anti-chicken (1:1000; Thermo Fisher Scientific Cat# A-11039,
235 RRID:AB_2534096) alone for 2 h at room temperature or 24 h at 4°C.
236 Sections were then rinsed for 5 min, first in PBS-Tx 3 times then PBS 2 times
237 before being mounted in Vectorshield Mounting Medium (Vector
238 Laboratories). Confocal laser scanning microscopy was performed using a
239 Leica SP confocal microscope. Images were taken at a resolution of 1,024 ×

240 1,024 and processed using Leica Confocal Software (Leica Microsystems),
241 Adobe Photoshop CS3 (Adobe Systems) and ImageJ. Anatomical localization
242 of optical fibres was assessed by examining the tracts in combination with
243 immunolabelling for tyrosine hydroxylase to identify VTA dopamine neurons.

244

245 *cFos immunostaining*

246 7 male mice underwent unilateral surgery. Following 2 weeks of recovery,
247 mice were handled daily for 2 weeks and followed the standard habituation
248 protocol. On the test day, mice were tethered to the laser via patchcords and
249 placed in their designated testing chamber with a paper liner. Following a 15
250 min habituation period, 30 min of phasic stimulation started. The mice were
251 left for 30 min then anaesthetised, transcardially perfused, the brain removed
252 and sectioned at 70 μ m on a cryostat. Sections were processed as above.
253 Three areas were selected in the VTA corresponding to medial, ventral and
254 dorsolateral regions. TH+ve cells were identified and then checked for cFos.
255 Following cFos analysis, mCherry expression was checked in selected brain
256 slices.

257

258 *Conditioned place preference*

259 Following surgery, mice were housed in pairs or trios. They were handled and
260 scruffed for a week prior to the test day. A biased conditioned place
261 preference (CPP) was then performed based on Tsai *et al.* (2009) with 4 days
262 of conditioning. A three compartment CPP setup was used (Med Assoc. Inc.).
263 The white and black compartments were scented with lemon and ethanol
264 respectively. On day 1, mice were placed in the central grey compartment for

265 2 min, and gates were then opened allowing free exploration of all 3
266 compartments for 15 min. The time spent in each area was recorded and their
267 preferred chamber was noted. On the first day of conditioning (day 2), the
268 mice were placed in one compartment and the following day (day 3) the other
269 compartment for 30 min. They were tethered in both compartments but only
270 stimulated in the compartment they showed least preference for on day 1.
271 Laser power output was 2 mW from the tip. Conditioning was continued for
272 days 4 and 5. On day 6, the mice were tested for preference. As for day 1,
273 they were placed in the central grey compartment for 2 min, gates opened
274 and then allowed to explore for 15 min without stimulation. Time spent in each
275 compartment on day 1 and day 6 was analysed to assess whether the mice
276 preferred the compartment where they had received stimulation. Locomotor
277 activity on the conditioning days was analysed to assess whether stimulation
278 increased activity.

279

280 *Open field activity*

281 Each mouse was tested in a custom-made wooden open field arena 45 cm x
282 45 cm with 30 cm walls. Mice were habituated to the arena for 20 min and
283 then injected i.p. with either CNO (0.1 mg/kg) or saline and immediately
284 placed back in the arena for a 60 min test session. hM3Dq-expressing mice
285 were previously injected with different CNO doses (ranging from 0.1-
286 0.5mg/kg) or saline. Drug allocation (saline vs CNO) was randomized prior to
287 each dose tested (data not shown). The groups were then re-randomized and
288 injected with a dose of 0.05mg/kg CNO or saline (data shown). Their activity
289 was recorded using a video camera suspended above the arena that

290 interfaced with a computerized tracking system (Ethovision XT, Noldus). Total
291 distance travelled was recorded in 1 min bins and analysed in 5 min bins.

292

293 *In vitro electrophysiology*

294 Ten to twelve week old male mice (DATcre+ for optogenetic and
295 chemogenetic validation experiments; C57BL6 for salt-deprivation and fasting
296 experiments) were anaesthetised by Euthatal following isoflurane. The brain
297 was removed by decapitation following a quick transcardial perfusion with ice-
298 cold artificial cerebrospinal fluid (aCSF, composition in mM, NaCl 120, KCl
299 3.5, NaH₂PO₄ 1.25, NaHCO₃ 25, glucose 10, MgCl₂ 1, CaCl₂ 2) fully
300 equilibrated with carbogen gas (95% oxygen and 5% carbon dioxide). Two or
301 three horizontal brain slices (190 μ m thickness) encompassing the VTA were
302 obtained using a vibratome (Leica VT1000S; Leica Microsystems, Wetzlar,
303 Germany) and were incubated for 15min in carbogenated NMDG-HEPES
304 recovery solution (NMDG 93, KCl 2.5, NaH₂PO₄ 1.2, NaHCO₃ 30, HEPES
305 20, Glucose 25, sodium ascorbate 5, Thiourea 2, Sodium pyruvate 3, MgSO₄
306 10, CaCl₂ 0.5, pH7.3, 300mOsm, 33°C) (Zhao et al., 2011), and transferred
307 back to aCSF. Slices were maintained in a standard custom-made
308 maintenance chamber gently and continuously aerated with carbogen gas for
309 at least 60 min at room temperature (20–22 °C) before being used for
310 electrophysiology.

311

312 Slices were transferred to a submersion recording chamber and were
313 continuously perfused at a rate of 2-4 ml/min with fully oxygenated aCSF at
314 32°C. Neurons were visualized using infra-red differential interference

315 contract (IR-DIC) under an upright microscope (Olympus BXWI 51, Japan)
316 equipped with a 40x objective (0.8 numerical aperture), an IR filter, DIC optics
317 and a charge coupled device (CCD) video camera (Watac). For visualising
318 recorded neurons, 0.1% neurobiotin (Vectorlab) was added to all intercellular
319 solutions.

320

321 Whole-cell patch-clamp recordings were performed with a Multiclamp 700B
322 amplifier (Molecular Devices, CA) and an Axopatch 200A amplifier (Axon
323 Instruments). The signals were sampled at 20 kHz and low-pass filtered at 1
324 kHz. Series resistance (R_s) and input resistance (R_{in}) were frequently
325 monitored throughout the experiments via a 10mV, 250ms hyperpolarizing
326 step. Any large changes in holding current or noise characteristics were taken
327 as early signs of cell loss and recordings were terminated. Experiments were
328 also terminated if R_s exceeded 35 M Ω or if R_{in} changed more than 15% after
329 break in the whole-cell mode. R_s (typical values of 10-30 M Ω) was
330 compensated by 60-70% in the majority of the experiments. Membrane
331 capacitance (C_m) was measured under voltage clamp at -50 mV using a
332 hyperpolarizing 10 mV, 250 ms step. C_m was measured from the change in
333 membrane charge taken from the integrated capacity transients (pClamp,
334 Molecular Devices). All potentials cited here have not been corrected for liquid
335 junction potentials (estimated using pClamp calculator as 9.2 mV). Slices
336 were incubated in drug cocktails for minimum of 15 min prior to recording.

337

338 For evoked postsynaptic currents, a bipolar stimulating electrode (FHC) was
339 placed 100-300 μ m rostral to the recorded neuron, and used to stimulate

340 afferents at 0.03 Hz. Stimulus intensity was controlled using an ISO-flex
341 stimulus isolator (AMPI) and adjusted to evoke monosynaptic events.
342 Therefore stimulation only elicited currents with a single peak, and fast rise
343 and decay kinetics. GABA_A receptors were blocked by picrotoxin (100 μ M).
344 The whole-cell recording electrode (4-7 M Ω) was filled with an internal
345 solution containing (in mM): CsCH₃SO₃ 128, HEPES 20, TEA-Cl 5, NaCl 2.8,
346 EGTA 0.4, MgATP 2, NaGTP 0.5 (pH 7.25- 7.35, 280-285 mOsm). The
347 putative VTA dopamine neurons were initially voltage clamped at -70mV and
348 gradually shifted to +40mV. Once a stable clamp was achieved, a single
349 stimulus at an interval of 20s was applied and eEPSCs were obtained. After at
350 least 10 sweeps of stable current recording were successfully made, d-AP5
351 (50 μ M) was applied to the slice for a minimum of 10 min and pure AMPAR-
352 mediated eEPSCs were recorded. NMDAR-mediated currents were obtained
353 by a digital subtraction between the mixed current and the AMPAR current
354 using Clampfit 10.2 (Molecular Devices; Sunnyvale, CA, USA). The
355 AMPAR/NMDAR ratio was calculated by dividing the peak amplitude of the
356 average AMPAR-mediated eEPSC by the peak amplitude of the NMDAR-
357 mediated eEPSC.

358

359 For optogenetic and pharmacogenetic stimulation, VTA dopamine neurons
360 were identified by the expression of mCherry or YFP. The whole-cell
361 recording electrode (5-7 M Ω) was filled with an internal solution containing (in
362 mM): K-Gluconate 140, KCl 5, HEPES 10, EGTA 0.1, MgCl₂ 2, MgATP 2,
363 NaGTP 0.2 (pH 7.3-7.4, 280-285 mOsm). A blue light (470nm) was delivered
364 by TTL-control from a microscope-mounted LED to the entire field through the

365 objective. After the achievement of stable current clamp, a rapid flash of light
366 for 5ms (25Hz) with an inter-stimulus interval of 5s was given for 4 times at
367 the 60s inter-sweep interval. The light intensity was adjusted according to the
368 magnitude of its response. The yellow light (585 nm) was delivered by TTL-
369 control from a microscope-mounted LED to the entire field through the
370 objective. After the stable current clamp was achieved, +75pA current step
371 (12s) was given and 2 sets of 8s continuous light stimulation was applied at
372 2s intervals. The light intensity was adjusted according to the magnitude of its
373 response. For the hM4Di experiments, 100 μ M CNO (C0832, Sigma) was
374 pipetted directly into the bath chamber after obtaining a stable spontaneous
375 firing for 10min. After the membrane potential was hyperpolarised, CNO was
376 washed off with aCSF. For hM3Dq, 1 μ M CNO was perfused onto the brain
377 slice after obtaining a stable spontaneous firing for 10 mins and change of
378 membrane potential and firing frequency was monitored for 20 min.

379

380 *In vivo electrophysiology*

381 C57BL6 mice were anaesthetised with isoflurane and maintained with
382 urethane during recording. Body temperature was maintained at 35 $^{\circ}$ C \pm 0.5
383 with a homeothermic heating blanket connected to a rectal thermometer
384 (Harvard Apparatus, Edenbridge, Kent UK). Hydration was maintained with
385 injections of 0.45% saline or 0.9% saline every 3h for mice in the salt depleted
386 experiment and mice in the overnight fasted experiment. A craniotomy was
387 performed above the VTA, removing a rectangular section of skull 3-3.6 mm
388 from bregma, and 0.5 mm either side of the midline in length, avoiding
389 damage to the underlying dura and mid-sagittal sinus. A glass electrode was

390 then positioned ± 0.4 mm mediolateral to bregma and within the range of -3.2
391 to -3.5 mm anterior-posterior to bregma. The glass electrode was then
392 lowered at a speed of $10\mu\text{m/s}$ to a depth of -3.5 mm from the dura. The
393 electrode was then slowly lowered at $1\mu\text{m/s}$, stopping at spike detection.
394 Extracellular recordings were made with glass microelectrodes (tip diameter,
395 1-1.5 μm ; 15-25 M Ω) lowered into the VTA with a micromanipulator (single-
396 axis IVM) controlled via LINLAB software and a PatchPad (all from Scientifica,
397 Uckfield, UK). Signals were AC-coupled, amplified ($\times 1000$) and bandpass
398 filtered (0.3-5 kHz) with a Neurolog system (NL102G head-stage and DC
399 preamplifier; Digitimer), and acquired on-line with a Micro1401 interface and
400 SPIKE2 software (v6; Cambridge Electronic Design, Cambridge, UK). Mains
401 noise (50 Hz) was eliminated with 'Humbug' filters (Quest Scientific, North
402 Vancouver, BC, Canada). Electrophysiological recordings were collected
403 from putative dopamine neurons (identified using electrophysiological criteria;
404 Ungless & Grace, 2012) sampled using multiple penetrations within the VTA
405 in a random order across an AP gradient of -3.2 to -3.5 mm in the left
406 hemisphere and right hemisphere. Neurons were recorded once their baseline
407 firing had stabilized, data were collected for a 3 min spike train. Five spike
408 firing parameters were extracted and analysed from in vivo recordings: firing
409 rate, coefficient of variation of the interspike interval (CV ISI), spike waveform
410 shape and duration from onset (defined as a change of $>0.02\text{mV}$ from
411 baseline) to the negative trough (Ungless *et al.*, 2004) and percentage of
412 spikes within a burst (Grace & Bunney, 1984). Single unit recordings were
413 performed by an experimenter blind to condition. All parameters were
414 analysed with scripts and algorithms within Spike2 (CED, Cambridge, UK).

415

416 *Experimental Design and Statistical Analyses*

417 Behavioural data were analysed using a mixed ANOVA with Time and
418 Concentration, where appropriate to analysis, as within subjects factors; and
419 Genotype (DATcre⁺ vs DATcre⁻) as a between subjects factor. An ANOVA
420 was performed to test the consumed weight of the jellies, total beam breaks or
421 preference score (this is the intake of one concentration jelly over the course
422 of the session divided by total intake of the jellies in that session). Where
423 significant interactions were observed, follow-up pairwise comparisons were
424 conducted. Violations of sphericity were adjusted for using the Huynh-Feld
425 adjustment. Violations of Normality were assessed by plotting the residuals of
426 the data. All electrophysiological data were analysed using non-parametric
427 Mann-Whitney U tests. The significance level for all statistics was $p < 0.05$
428 (two-tailed).

429 Results

430

431 Optogenetic excitation of VTA dopamine neurons selectively 432 decreases intake of high concentration salt jellies during salt 433 appetite

434 To optogenetically excite VTA dopamine neurons, DATcre⁺ and DATcre⁻
435 mice (Turiault *et al.*, 2007) were stereotactically injected with a cre-dependent
436 adeno-associated virus (AAV) containing an EF1 α promoter-driven
437 channelrhodopsin (ChR2) fused to mCherry (AAV-ChR2-mCherry; Figure 1A).
438 We observed strong mCherry expression, and colocalisation with TH⁺
439 neurons, in VTA sections of DATcre⁺ mice (Figure 1B). We then confirmed
440 with *ex vivo* recordings that our stimulation protocol (Figure 1C) excited
441 identified VTA dopamine neurons (Figure 1D). Furthermore, following
442 photostimulation in awake behaving mice, we observed increased cFos
443 expression selectively in dopamine neurons, providing evidence of *in vivo*
444 activation (Figure 1E).

445

446 We next investigated the effect of optogenetically exciting dopamine neurons
447 on salt intake. Salt appetite was induced in mice by placing them on a low
448 sodium diet and administering the sodium-wasting loop diuretic furosemide
449 (Rowland *et al.*, 2004; Figure 1F). Salt intake was assessed using a three-
450 choice salt jelly assay with three different concentrations (0.3 M, 0.15 M, &
451 0.075 M NaCl; Figure 1F; no effect of genotype was observed on this assay in
452 the absence of stimulation; data not shown). Optogenetic excitation of VTA

453 dopamine neurons, initiated 5 min before exposure to salt jelly, selectively
454 decreased consumption of the 0.3 M salt jelly in DATcre+ mice compared to
455 DATcre- mice during the first 10 min of the test session, when salt intake was
456 greatest (Figure 1G-I). When mice were tested again one week later, in the
457 absence of photo-stimulation, no group difference was observed, indicating
458 that the effects of optogenetic stimulation were reversible (Figure 1J-L).

459

460 One possible explanation of our results is that stimulation of VTA dopamine
461 neurons induces an aversive state. Indeed, stimulation of mesocortical
462 dopamine neurons (or dorsal raphe dopamine neurons) can induce a
463 conditioned place aversion (Lammel *et al.*, 2012; Gunaydin *et al.*, 2014;
464 Matthews *et al.*, 2016). However, given the relatively lateral position of our
465 laser fibre we considered it unlikely that we were stimulating mesocortical
466 dopamine neurons. Nonetheless, we used a biased conditioned place
467 preference (CPP) test to assess the aversive properties of our optogenetic
468 stimulation protocol. DATcre+ and DATcre- mice injected with AAV-ChR2
469 were first habituated to the three-compartment apparatus and their preferred
470 compartment noted. The same optical stimulation procedure as used during
471 the behavioural salt-jelly tests was then conducted in the non-preferred
472 compartment for two days with alternating days in the preferred compartment
473 without stimulation (Figure 1M). Following this, mice were tested for their
474 compartment preference in the absence of optical stimulation. We replicated
475 the effect of Tsai *et al.*, 2009) demonstrating that DATcre+ mice spent an
476 increased amount of time in the compartment where they received stimulation
477 versus time spent in this compartment prior to stimulation, whereas DATcre-

478 mice spent a similar amount of time in the stimulation compartment before
 479 and after conditioning (Figure 1N). This suggests that VTA dopamine neuron
 480 stimulation does not result in an aversive state.

481

482 The reduction in salt intake with optogenetic excitation of VTA dopamine
 483 neurons might be attributed to a general increase in locomotor activity
 484 competing with consumption (Carlton, 1963). However, analysis of locomotor
 485 activity during the four conditioning days revealed no differences in total
 486 activity between DATcre⁺ and DATcre⁻ mice, with or without stimulation
 487 (Figure 1P).

488

489 **Chemogenetic inhibition of VTA dopamine neurons does not affect** 490 **intake of high concentration salt jellies during salt appetite**

491 Next, we wanted to examine the effects of inhibition of VTA dopamine
 492 neurons on salt intake. To ensure robust inhibition of dopamine neurons we
 493 used a chemogenetic approach which tonically inhibits the spontaneous
 494 activity of neurons (Stachniak *et al.*, 2014). A cre-dependent adeno-
 495 associated virus (AAV) containing the Gi-coupled human M4 muscarinic
 496 DREADD coding sequence (hM4Di; a G-protein coupled receptor that
 497 decreases cell excitability) conjugated to the fluorescent protein mCherry
 498 (AAV-hM4Di-mCherry), was injected into the VTA of DATcre⁺ and DATcre⁻
 499 mice (Figure 2A). We observed strong mCherry expression, and
 500 colocalisation with TH⁺ neurons, in VTA sections of DATcre⁺ mice (Figure
 501 2B). We then confirmed with *ex vivo* recordings that application of CNO
 502 inhibited action potential firing of identified VTA dopamine neurons (Figure

503 2C). CNO was injected 30 min prior to testing, and had no effect on intake of
504 jellies (Figure 2D and 2E). As no obvious change in behaviour was observed
505 during the salt assay, we wanted to confirm we had an effective CNO dose to
506 activate hM4Di *in vivo*. The same mice were placed in an open field chamber
507 for 20 min, then injected with the same dose of CNO as used previously and
508 returned to the chamber for 60 min. DATcre+ mice demonstrated significant
509 decreases in their locomotor activity compared to DATcre- mice, suggesting
510 that our chemogenetic approach was capable of inhibiting dopamine neurons
511 (Figure 2F). We conclude, therefore, that inhibiting dopamine neurons does
512 not affect salt intake.

513 We also carried out complimentary chemogenetic experiments to
514 excite dopamine neurons, by expressing hM3Dq in the VTA (Figure 3A-C).
515 However, this manipulation induced very high levels of locomotor activity
516 (consistent with previous reports; Wang *et al.*, 2013) confounding
517 interpretation of the apparent reduction in intake seen across all salt jelly
518 concentrations (Figure 3D-F). This effect of chemogenetic excitation on
519 locomotion, not seen with optogenetic excitation, may be due to the different
520 temporal dynamics of the chemogenetic approach which is likely to have a
521 slower onset and offset than the optogenetic stimulation, and/or the possibility
522 that the chemogenetic approach excited a larger population of dopamine
523 neurons compared to the more localised optogenetic approach.

524

525 **Optogenetic excitation of VTA dopamine neurons selectively**
526 **decreases intake of high concentration sucrose jellies following an**
527 **overnight fast**

528 We next sought to test whether the effects of optogenetic excitation of VTA
529 dopamine neurons generalised to other types of appetite, in particular appetite
530 for sucrose following an overnight fast. DATcre⁺ and DATcre⁻ mice were
531 again injected with AAV-ChR2 in the VTA, implanted with optical fibres, and
532 then allowed to recover for one week. Mice were then handled and habituated
533 to the testing apparatus and sucrose jellies as in the salt experiment. At ~
534 4pm the day prior to testing, home-cage chow was removed and mice were
535 fasted overnight. The following day, optogenetic excitation of VTA dopamine
536 neurons, which began 5 min prior to testing, selectively decreased
537 consumption of the high concentration sucrose jelly (assayed using three
538 jellies of different sucrose concentrations: 10%, 20%, and 30%) in DATcre⁺
539 mice compared to DATcre⁻ mice (Figure 4A-B). This selective decrease in
540 consumption of the high concentration sucrose jelly in DATcre⁺ mice was
541 observed during the first 10 min of the session when appetite was strongest
542 (Figure 4C). These results parallel those seen during salt appetite, suggesting
543 that excitation of VTA dopamine neurons may have a general effect on
544 appetites.

545

546 **Salt appetite and sucrose appetite do not affect firing activity or** 547 **excitatory synaptic strength in dopamine neurons**

548 Given the effect of increasing firing activity on salt and sucrose intake, we
549 wanted to know what effect these appetites had on baseline dopamine neuron
550 firing activity. Interestingly, despite the intensive study of the role of dopamine
551 neurons in reward, little is known about how appetite affects their firing
552 activity. One recent study reported an increase in burst firing, but not firing

553 rate, of substantia nigra dopamine neurons in response to prolonged food
554 restriction, but not an overnight fast (Branch *et al.*, 2013). In addition, they
555 observed an increase in excitatory synaptic strength following food restriction.
556 We, therefore, examined *in vivo* firing activity and *ex vivo* excitatory synaptic
557 strength in putative dopamine neurons in the VTA either after an overnight
558 fast or during salt appetite. First, we conducted single-unit extracellular
559 recordings of action potential activity from putative dopamine neurons in the
560 VTA of anaesthetised mice. We observed no effect of either an overnight fast
561 or salt appetite on firing frequency, burst activity, or firing regularity (Figure
562 5A-F). Second, we conducted whole-cell recordings of synaptic currents in
563 putative dopamine neurons in *ex vivo* acute brain slices. In particular, we
564 assayed AMPAR/NMDAR ratios (a commonly used measure of synaptic
565 strength in dopamine neurons; Ungless *et al.*, 2001; Branch *et al.*, 2013). We
566 observed no effect of either an overnight fast or salt appetite on
567 AMPAR/NMDAR ratios (Figure 5G-J). Taken together, these results suggest
568 that the acute induction of either a salt or sucrose appetite does not affect
569 baseline firing activity, or excitatory synaptic strength, in VTA dopamine
570 neurons.

571

572 **Optogenetic excitation of VTA dopamine neurons does not disrupt** 573 **salt concentration preference following an overnight fast**

574 Our results show that optogenetic excitation of VTA dopamine neurons
575 selectively can reduce intake of both high-concentration salt and high-
576 concentration sucrose. One possible interpretation of this effect is that the
577 optogenetic excitation somehow leads to the inability to perceive differences

578 in concentration or to exhibit preference behaviour. To test this, following an
579 overnight fast, we presented mice with three jellies of differing salt
580 concentration, but the same concentration of sucrose (Jelly 1 - 0.075 M NaCl
581 + 10 % sucrose; Jelly 2 - 0.15 M NaCl +10 % sucrose; Jelly 3 - 0.3 M NaCl +
582 10 % sucrose) to assess whether mice could discriminate the differing
583 concentrations of NaCl. DATcre+ mice and DATcre- mice exhibited a clear
584 preference for the low concentration salt jelly (0.075 M NaCl + 10 % sucrose),
585 as would be expected in this salt replete state (Figure 6A-C). Importantly, as
586 expected, optogenetic excitation of dopamine neurons reduced overall jelly
587 intake in the DATcre+ mice, but there was no interaction with salt
588 concentration. Furthermore, when intake was expressed as preference scores
589 it was clear that there was no effect of optogenetic stimulation on preference
590 (Figure 6D).

591 Discussion

592 Here we showed that optogenetic excitation of VTA dopamine neurons
593 specifically reduced intake of high concentration salt during salt appetite. This
594 effect was relatively rapid (i.e., occurring within minutes of stimulation) and
595 reversible (i.e., it was not present a week later in the absence of excitation).
596 We did not detect any aversive properties of the optogenetic excitation of VTA
597 dopamine neurons, nor did it lead to an increase in locomotor activity. We
598 also found that chemogenetic inhibition of dopamine neurons had no effect on
599 salt-intake. Furthermore, we found that optogenetic excitation of VTA
600 dopamine neurons also reduced intake of a high concentration sucrose jelly
601 following an overnight fast, complimenting recent reports of optogenetic
602 excitation of VTA dopamine neurons inhibiting sucrose drinking (Mikhailova *et*
603 *al.*, 2016) and chemogenetic excitation of dopamine neurons inhibiting food
604 intake (Boekhoudt *et al.*, 2017). Taken together, these results suggest a
605 general role of VTA dopamine neuron excitation in modulating intake during
606 appetite. Importantly, we found that the specific reduction in intake of the high
607 salt concentration jelly during salt appetite was not due to a disruption in the
608 ability of the mice to demonstrate a preference. Although it is not possible for
609 us to know which projection-specific populations of dopamine neurons we
610 excited, it should be noted that because of the position of our optic fibres it is
611 likely that we preferentially stimulated dopamine neurons in more lateral parts
612 of the VTA, which are more likely to project to the striatum, and avoided more
613 medially located mesocortical dopamine neurons which can drive aversive
614 behaviour (Lammel *et al.*, 2012). Consistent with this, we found that our

615 stimulation protocol could generate a conditioned place preference, similar to
616 that seen in previous studies (e.g., Tsai *et al.*, 2009).

617

618 Despite the intensive study of the role of VTA dopamine neurons in reward
619 processing, relatively little is known about how appetite affects their firing
620 activity or synaptic properties. Our *in vivo* recordings in both salt-depleted and
621 fasted mice revealed no effect of these appetite manipulations on
622 spontaneous firing activity of putative VTA dopamine neurons. Consistent with
623 this, an overnight fast does not change the spontaneous firing of substantia
624 nigra dopamine neurons (Branch *et al.*, 2013). However, more prolonged
625 fasting or long-term food restriction has been shown to increase burst firing of
626 dopamine neurons (Marinelli *et al.*, 2006; Branch *et al.*, 2013). Taken together
627 these findings suggest that an acute appetite does not change dopamine
628 neuron firing activity, but that more chronic manipulations of appetite may
629 increase dopamine neuron firing activity possibly by engaging stress-related
630 mechanisms. The excitatory inputs of midbrain dopamine neurons are highly
631 sensitive to motivationally-significant events (e.g., a single exposure to
632 addictive drugs such as cocaine, reward learning, stress, and long-term food
633 restriction; Ungless *et al.*, 2001; Stuber *et al.*, 2008; Saal *et al.*, 2003; Branch
634 *et al.*, 2013). We, therefore, tested whether manipulations of appetite used in
635 this study changed synaptic strength in VTA dopamine neurons. No change
636 was seen in AMPAR/NMDAR ratios following overnight fast or salt depletion,
637 indicating that an acute appetite *per se* does not affect glutamatergic synaptic
638 strength in dopamine neurons. We sampled from a broad population of
639 putative dopamine neurons in the lateral parts of the VTA with unknown

640 projection targets, and it is therefore possible that our sample contained some
641 mesocortical dopamine neurons which do not exhibit synaptic plasticity to
642 appetitive events (Lammel *et al.*, 2011).

643

644 Our finding that optogenetic excitation of VTA dopamine neurons resulted in a
645 reduction in intake during appetite is consistent with reports of suppressed
646 intake with the systemic administration of either d-amphetamine (Kraeuchi *et al.*, 1985 *et al.*), cocaine (Wellman *et al.*, 2002 *et al.*) or dopamine receptor
647 agonists (Chen *et al.*, 2008 ; Cincotta *et al.*, 1997, Kuo, 2002). A number of
648 studies have attributed the anorexic effects of amphetamine to its modulation
649 of the dopaminergic system. Supporting this, dopamine antagonists
650 (Leibowitz, 1975; Garattini *et al.*, 1976); electrolytic lesions and 6-OHDA
651 lesions of the nigrostriatal pathway (Carey & Goodall, 1975; Fibiger *et al.*,
652 1973) and 6-OHDA lesions of the neostriatum (Joyce & Iversen, 1984) all
653 alleviate the hypophagic effects of amphetamine. Direct evidence of the role
654 of dopamine in amphetamine-induced hypophagia is found in dopamine-
655 deficient (DD) mice that are insensitive to the hypophagic effects of
656 amphetamine (Cannon *et al.*, 2004). Moreover, viral restoration of dopamine
657 to the caudate putamen of these mice reinstated amphetamine-induced
658 hypophagia implicating dopamine signalling within the dorsal striatum in this
659 phenomenon (Cannon *et al.*, 2004). The specificity of these effects to the
660 dopamine system within this region is supported by the failure to ameliorate
661 amphetamine-induced hypophagia using a variety of manipulations targeting
662 alternative neurochemical systems thought to be altered by amphetamine
663 administration (Cannon *et al.*, 2004; Sotak *et al.*, 2005). Furthermore, no
664

665 effect was found with viral restoration of dopamine signalling in the nucleus
666 accumbens, which is consistent with a large body of literature on the failure to
667 disrupt the primary motivational properties of food with lesions to the nucleus
668 accumbens or dopamine antagonism within this region (Caine & Koob, 1994;
669 Roberts *et al.*, 1977; Salamone *et al.*, 2005).

670

671 A reduction in intake with increased dopamine activity may appear
672 counterintuitive considering dopamine's role in behavioural activation
673 (Salamone *et al.*, 2009; Robbins & Everitt, 2007; Syed *et al.*, 2016) and food-
674 seeking behaviour (Wise, 2006). However, it has been proposed that optimal
675 levels of dopaminergic activity are essential for the activation of
676 motivationally-relevant behaviour (Heffner *et al.*, 1977, Robbins, 2010;
677 Palmiter, 2007). The activation of motivated behaviour is dependent on an
678 inverted u-shaped function of dopamine activity. In the case of appetite,
679 optimal levels of dopamine activity result in food-seeking behaviour (Roitman
680 *et al.*, 2004). However, too little dopamine, exemplified in dopamine-deficient
681 mice, inhibits feeding as these mice die of starvation unless maintained with
682 daily injections of L-DOPA (Szczypka *et al.*, 1999; Zhou & Palmiter, 1995).
683 Too much dopamine, as may be the case with the present optogenetic study
684 and previous studies (van der Hoek & Cooper, 1994; Alnaser & Cooper, 1994;
685 Scislowski *et al.*, 1999; Mikhailova *et al.*, 2016), also results in inhibition of
686 intake during appetite. Our optogenetic excitation protocol may, therefore,
687 have resulted in dopamine activity beyond the optimal levels for engaging in
688 food consumption during a state of appetite. Importantly, the use of
689 pharmacological manipulations often produces confounding results to those

690 observed with more rapid optogenetic manipulations (Otchy *et al.*, 2015). Our
691 findings, therefore, usefully build on these previous pharmacological
692 manipulations by showing that direct excitation of dopamine neurons can
693 relatively rapidly suppress intake. Lastly, our observation that chemogenetic
694 inhibition had no effect on intake is reminiscent of the failure to affect food
695 consumption with 6-OHDA lesion and dopamine antagonism of the striatum
696 (Baldo *et al.*, 2002; Aberman & Salamone, 1999).

697

698 We propose that optogenetic excitation of VTA dopamine neurons reduces
699 salt or sucrose appetite such that mice are no longer driven to consume a
700 high concentration of a relevant reinforcer. Alternative theoretical accounts of
701 these results could be that increased tonic dopamine levels switch behaviour
702 from exploitation of a current food resource to exploration of the environment
703 for alternative food resources (Cohen *et al.*, 2007; Beeler *et al.*, 2010; Beeler
704 *et al.*, 2012; Humphries *et al.*, 2012) perhaps by increasing behavioural vigor
705 (Niv *et al.*, 2007). Although it is difficult to separate the different contributions
706 of phasic versus tonic dopamine in our task, and the effects of our stimulation
707 protocol on them, this account of our results seems unlikely for several
708 reasons. First, optogenetic excitation of VTA dopamine neurons during the
709 stimulation days of the CPP test showed no difference in locomotor activity
710 compared to non-stimulated sessions. Second, intake was decreased
711 throughout the 30 min intake test. If stimulation had led to more exploration,
712 but no suppression of appetite, then we might have expected mice to
713 eventually return to consume the jellies. Another possibility we addressed is
714 that the stimulation procedure disrupted the ability of the mice to demonstrate

715 preferential consumption of one jelly. However, when fasted mice were
716 presented with three jellies with differing concentrations of salt, but the same
717 concentration of sucrose, optogenetic excitation of VTA dopamine neurons
718 did not affect preferential consumption of the low concentration salt jelly. This
719 suggests the ability to exhibit preference behaviour is unaffected by
720 optogenetic stimulation of dopamine neurons and is consistent with the
721 observation that hyperdopaminergic mutant mice exhibit normal hedonic
722 'liking' responses to sweet tastes (Pecina *et al.*, 2003).

723

724 The reduction in intake of both salt and sucrose with optogenetic excitation of
725 VTA dopamine neurons suggests a common mechanism may have been
726 disrupted for both nutrient rewards. Dopamine within the dorsal striatum has
727 been shown to play a specific role in feeding behaviour as viral restoration of
728 dopamine signalling in dopamine deficient mice rescues feeding behaviour
729 (Cannon *et al.*, 2004). Our optical fibre was positioned preferentially above the
730 dorsolateral ventral tegmental area. Considering the topography of projections
731 of the ventral tegmental area it is possible that we excited neurons projecting
732 to more dorsal regions of the striatum. Activation of dopamine projections
733 from the dorsolateral VTA to more dorsal regions of the striatum may provide
734 a nutritional signal despite a state of hunger such that mice are no longer
735 motivated to consume the highest concentration jelly.

736 **References**

- 737 Aberman, J.E. & Salamone, J.D. (1999) Nucleus accumbens dopamine
 738 depletions make rats more sensitive to high ratio requirements but do
 739 not impair primary food reinforcement. *Neuroscience*, 92, 545-552.
 740
- 741 Adamantidis, A.R., Tsai, H.C., Boutrel, B., Zhang, F., Stuber, G.D., Budygin,
 742 E.A., Tourino, C., Bonci, A., Deisseroth, K. & de Lecea, L. (2011)
 743 Optogenetic interrogation of dopaminergic modulation of the multiple
 744 phases of reward-seeking behavior. *The Journal of neuroscience : the*
 745 *official journal of the Society for Neuroscience*, 31, 10829-10835.
 746
- 747 Alderman, M.H. & Cohen, H.W. (2012) Dietary sodium intake and
 748 cardiovascular mortality: controversy resolved? *Curr Hypertens Rep*,
 749 14, 193-201.
 750
- 751 Alnaser, H.A. & Cooper, S.J. (1994) A-68930, a Novel, Potent Dopamine D1
 752 Receptor Agonist - a Microstructural Analysis of Its Effects on Feeding
 753 and Other Behavior in the Rat. *Behav Pharmacol*, 5, 210-218.
 754
- 755 Asayama, K., Stolarz-Skrzypek, K., Persu, A. & Staessen, J.A. (2014)
 756 Systematic review of health outcomes in relation to salt intake
 757 highlights the widening divide between guidelines and the evidence.
 758 *Am J Hypertens*, 27, 1138-1142.
 759

- 760 Baldo, B.A., Sadeghian, K., Basso, A.M. & Kelley, A.E. (2002) Effects of
761 selective dopamine D1 or D2 receptor blockade within nucleus
762 accumbens subregions on ingestive behavior and associated motor
763 activity. Behavioural brain research, 137, 165-177.
- 764
- 765 Beeler, J.A., Daw, N., Frazier, C.R. & Zhuang, X. (2010) Tonic dopamine
766 modulates exploitation of reward learning. Frontiers in behavioral
767 neuroscience, 4, 170.
- 768
- 769 Beeler, J.A., Frazier, C.R. & Zhuang, X. (2012) Putting desire on a budget:
770 dopamine and energy expenditure, reconciling reward and resources.
771 Front Integr Neurosci, 6, 49.
- 772
- 773 Boekhoudt, L., Roelofs, T.J.M., de Jong, J.W., de Leeuw, A.E., Luijendijk,
774 M.C.M., Wolterink-Donselaar, I.G., van der Plasse, G. & Adan, R.A.H.
775 (2017) Does activation of midbrain dopamine neurons promote or
776 reduce feeding? Int J Obes (Lond).
- 777
- 778 Branch, S.Y., Goertz, R.B., Sharpe, A.L., Pierce, J., Roy, S., Ko, D., Paladini,
779 C.A. & Beckstead, M.J. (2013) Food restriction increases glutamate
780 receptor-mediated burst firing of dopamine neurons. The Journal of
781 neuroscience : the official journal of the Society for Neuroscience, 33,
782 13861-13872.
- 783

- 784 Caine, S.B. & Koob, G.F. (1994) Effects of mesolimbic dopamine depletion on
785 responding maintained by cocaine and food. *Journal of the*
786 *experimental analysis of behavior*, 61, 213-221.
- 787
- 788 Cannon, C.M., Abdallah, L., Tecott, L.H., During, M.J. & Palmiter, R.D. (2004)
789 Dysregulation of striatal dopamine signaling by amphetamine inhibits
790 feeding by hungry mice. *Neuron*, 44, 509-520.
- 791
- 792 Carey, R.J. & Goodall, E.B. (1975) Attenuation of amphetamine anorexia by
793 unilateral nigral striatal lesions. *Neuropharmacology*, 14, 827-834.
- 794
- 795 Carlton, P.L. (1963) Cholinergic mechanisms in the control of behavior by the
796 brain. *Psychological review*, 70, 19-39.
- 797
- 798 Chen, B.T., Bowers, M.S., Martin, M., Hopf, F.W., Guillory, A.M., Carelli, R.M.,
799 Chou, J.K. & Bonci, A. (2008) Cocaine but not natural reward self-
800 administration nor passive cocaine infusion produces persistent LTP in
801 the VTA. *Neuron*, 59, 288-297.
- 802
- 803 Cincotta, A.H., Tozzo, E. & Scislowski, P.W. (1997) Bromocriptine/SKF38393
804 treatment ameliorates obesity and associated metabolic dysfunctions in
805 obese (ob/ob) mice. *Life sciences*, 61, 951-956.
- 806

- 807 Cohen, J.D., McClure, S.M. & Yu, A.J. (2007) Should I stay or should I go?
808 How the human brain manages the trade-off between exploitation and
809 exploration. *Philos T R Soc B*, 362, 933-942.
- 810
- 811 Cone, J.J., Fortin, S.M., McHenry, J.A., Stuber, G.D., McCutcheon, J.E. &
812 Roitman, M.F. (2016) Physiological state gates acquisition and
813 expression of mesolimbic reward prediction signals. *Proceedings of the*
814 *National Academy of Sciences of the United States of America*.
- 815
- 816 Denton, D. (1982) *The hunger for salt*. New York: Springer.
- 817
- 818 Fibiger, H.C., Phillips, A.G. & Clouston, R.A. (1973) Regulatory deficits after
819 unilateral electrolytic or 6-OHDA lesions of the substantia nigra. *The*
820 *American journal of physiology*, 225, 1282-1287.
- 821
- 822 Garattini, S., Jori, A. & Samanin, R. (1976) Interactions of Various Drugs with
823 Amphetamine. *Ann Ny Acad Sci*, 281, 409-425.
- 824
- 825 Geerling, J.C. & Loewy, A.D. (2008) Central regulation of sodium appetite.
826 *Exp Physiol*, 93, 177-209.
- 827
- 828 Grace, A.A. & Bunney, B.S. (1984) The control of firing pattern in nigral
829 dopamine neurons: burst firing. *The Journal of neuroscience : the*
830 *official journal of the Society for Neuroscience*, 4, 2877-2890.
- 831

- 832 Gunaydin, L.A., Grosenick, L., Finkelstein, J.C., Kauvar, I.V., Fenno, L.E.,
833 Adhikari, A., Lammel, S., Mirzabekov, J.J., Airan, R.D., Zalocusky,
834 K.A., Tye, K.M., Anikeeva, P., Malenka, R.C. & Deisseroth, K. (2014)
835 Natural neural projection dynamics underlying social behavior. *Cell*,
836 157, 1535-1551.
- 837
- 838 Heffner, T.G., Zigmond, M.J. & Stricker, E.M. (1977) Effects of dopaminergic
839 agonists and antagonists of feeding in intact and 6-hydroxydopamine-
840 treated rats. *The Journal of pharmacology and experimental*
841 *therapeutics*, 201, 386-399.
- 842
- 843 Humphries, M.D., Khamassi, M. & Gurney, K. (2012) Dopaminergic Control of
844 the Exploration-Exploitation Trade-Off via the Basal Ganglia. *Front*
845 *Neurosci*, 6, 9.
- 846
- 847 Jarvie, B.C. & Palmiter, R.D. (2016) HSD2 neurons in the hindbrain drive
848 sodium appetite. *Nature neuroscience*.
- 849
- 850 Joyce, E.M. & Iversen, S.D. (1984) Dissociable Effects of 6-OHda-Induced
851 Lesions of Neostriatum on Anorexia, Locomotor-Activity and
852 Stereotypy - the Role of Behavioral Competition. *Psychopharmacology*,
853 83, 363-366.
- 854
- 855 Kraeuchi, K., Rudolph, K., Wirz-Justice, A. & Feer, H. (1985) Similarities in
856 feeding behavior of chronic methamphetamine treated and withdrawn

857 rats to VMH lesioned rats. Pharmacology, biochemistry, and behavior,
858 23, 917-920.

859

860 Kuo, D.Y. (2002) Co-administration of dopamine D1 and D2 agonists
861 additively decreases daily food intake, body weight and hypothalamic
862 neuropeptide Y level in rats. Journal of biomedical science, 9, 126-132.

863

864 Lammel, S., Ion, D.I., Roeper, J. & Malenka, R.C. (2011) Projection-specific
865 modulation of dopamine neuron synapses by aversive and rewarding
866 stimuli. Neuron, 70, 855-862.

867

868 Lammel, S., Lim, B.K., Ran, C., Huang, K.W., Betley, M.J., Tye, K.M.,
869 Deisseroth, K. & Malenka, R.C. (2012) Input-specific control of reward
870 and aversion in the ventral tegmental area. Nature, 491, 212-217.

871

872 Leibowitz, S.F. (1975) Amphetamine: possible site and mode of action for
873 producing anorexia in the rat. Brain research, 84, 160-167.

874

875 Ma, Y., He, F.J. & MacGregor, G.A. (2015) High salt intake: independent risk
876 factor for obesity? Hypertension, 66, 843-849.

877

878 Marinelli, M., Rudick, C.N., Hu, X.T. & White, F.J. (2006) Excitability of
879 dopamine neurons: modulation and physiological consequences. CNS
880 & neurological disorders drug targets, 5, 79-97.

881

- 882 Matthews, G.A., Nieh, E.H., Vander Weele, C.M., Halbert, S.A., Pradhan,
 883 R.V., Yosafat, A.S., Glober, G.F., Izadmehr, E.M., Thomas, R.E., Lacy,
 884 G.D., Wildes, C.P., Ungless, M.A. & Tye, K.M. (2016) Dorsal Raphe
 885 Dopamine Neurons Represent the Experience of Social Isolation. *Cell*,
 886 164, 617-631.
- 887
- 888 McCarron, D.A., Kazaks, A.G., Geerling, J.C., Stern, J.S. & Graudal, N.A.
 889 (2013) Normal range of human dietary sodium intake: a perspective
 890 based on 24-hour urinary sodium excretion worldwide. *Am J*
 891 *Hypertens*, 26, 1218-1223.
- 892
- 893 Mikhailova, M.A., Bass, C.E., Grinevich, V.P., Chappell, A.M., Deal, A.L.,
 894 Bonin, K.D., Weiner, J.L., Gainetdinov, R.R. & Budygin, E.A. (2016)
 895 Optogenetically-induced tonic dopamine release from VTA-nucleus
 896 accumbens projections inhibits reward consummatory behaviors.
 897 *Neuroscience*, 333, 54-64.
- 898
- 899 Nation, H.L., Nicoleau, M., Kinsman, B.J., Browning, K.N. & Stocker, S.D.
 900 (2016) DREADD-induced activation of subfornical organ neurons
 901 stimulates thirst and salt appetite. *Journal of neurophysiology*, 115,
 902 3123-3129.
- 903
- 904 Nawaratne, V., Leach, K., Suratman, N., Loiacono, R.E., Felder, C.C.,
 905 Armbruster, B.N., Roth, B.L., Sexton, P.M. & Christopoulos, A. (2008)
 906 New insights into the function of M4 muscarinic acetylcholine receptors

907 gained using a novel allosteric modulator and a DREADD (designer
908 receptor exclusively activated by a designer drug). *Molecular*
909 *pharmacology*, 74, 1119-1131.

910

911 Niv, Y., Daw, N.D., Joel, D. & Dayan, P. (2007) Tonic dopamine: opportunity
912 costs and the control of response vigor. *Psychopharmacology*, 191,
913 507-520.

914

915 Otchy, T.M., Wolff, S.B., Rhee, J.Y., Pehlevan, C., Kawai, R., Kempf, A.,
916 Gobes, S.M. & Olveczky, B.P. (2015) Acute off-target effects of neural
917 circuit manipulations. *Nature*, 528, 358-363.

918

919 Palmiter, R.D. (2007) Is dopamine a physiologically relevant mediator of
920 feeding behavior? *Trends Neurosci*, 30, 375-381.

921

922 Pecina, S., Cagniard, B., Berridge, K.C., Aldridge, J.W. & Zhuang, X. (2003)
923 Hyperdopaminergic mutant mice have higher "wanting" but not "liking"
924 for sweet rewards. *The Journal of neuroscience : the official journal of*
925 *the Society for Neuroscience*, 23, 9395-9402.

926

927 Richter, C. (1956) Salt appetite of mammals: Its dependence on instinct and
928 metabolism. In M. Autuori (Ed.), *L'instinct dans le comportement des*
929 *animaux de l'homme* (pp. 556-629). Paris: Masson et Cie., 556-629.

930

- 931 Robbins, T.W. (2010) From Behavior to Cognition: Functions of Mesostriatal,
932 Mesolimbic, and Mescortical Dopamine Systems *Dopamine Handbook*.
933 Oxford University Press, New York, pp. 203-214.
934
- 935 Robbins, T.W. & Everitt, B.J. (2007) A role for mesencephalic dopamine in
936 activation: commentary on Berridge (2006). *Psychopharmacology*
937 (Berl), 191, 433-437.
938
- 939 Roberts, D.C., Corcoran, M.E. & Fibiger, H.C. (1977) On the role of ascending
940 catecholaminergic systems in intravenous self-administration of
941 cocaine. *Pharmacology, biochemistry, and behavior*, 6, 615-620.
942
- 943 Roitman, M.F., Schafe, G.E., Thiele, T.E. & Bernstein, I.L. (1997) Dopamine
944 and sodium appetite: antagonists suppress sham drinking of NaCl
945 solutions in the rat. *Behavioral neuroscience*, 111, 606-611.
946
- 947 Roitman, M.F., Stuber, G.D., Phillips, P.E.M., Wightman, R.M. & Carelli, R.M.
948 (2004) Dopamine operates as a subsecond modulator of food seeking.
949 *Journal of Neuroscience*, 24, 1265-1271.
950
- 951 Rowland, N.E., Farnbauch, L.J. & Crews, E.C. (2004) Sodium deficiency and
952 salt appetite in ICR: CD1 mice. *Physiology & behavior*, 80, 629-635.
953

- 954 Saal, D., Dong, Y., Bonci, A. & Malenka, R.C. (2003) Drugs of abuse and
955 stress trigger a common synaptic adaptation in dopamine neurons.
956 *Neuron*, 37, 577-582.
- 957
- 958 Salamone, J.D., Correa, M., Farrar, A.M., Nunes, E.J. & Pardo, M. (2009)
959 Dopamine, behavioral economics, and effort. *Frontiers in behavioral*
960 *neuroscience*, 3, 13.
- 961
- 962 Salamone, J.D., Correa, M., Mingote, S.M. & Weber, S.M. (2005) Beyond the
963 reward hypothesis: alternative functions of nucleus accumbens
964 dopamine. *Current opinion in pharmacology*, 5, 34-41.
- 965
- 966 Scislowski, P.W.D., Tozzo, E., Zhang, Y., Phaneuf, S., Prevelige, R. &
967 Cincotta, A.H. (1999) Biochemical mechanisms responsible for the
968 attenuation of diabetic and obese conditions in ob/ob mice treated with
969 dopaminergic agonists. *Int J Obesity*, 23, 425-431.
- 970
- 971 Sotak, B.N., Hnasko, T.S., Robinson, S., Kremer, E.J. & Palmiter, R.D. (2005)
972 Dysregulation of dopamine signaling in the dorsal striatum inhibits
973 feeding. *Brain research*, 1061, 88-96.
- 974
- 975 Sparta, D.R., Stamatakis, A.M., Phillips, J.L., Hovelso, N., van Zessen, R. &
976 Stuber, G.D. (2011) Construction of implantable optical fibers for long-
977 term optogenetic manipulation of neural circuits. *Nat Protoc*, 7, 12-23.
- 978

- 979 Stachniak, T.J., Ghosh, A. & Sternson, S.M. (2014) Chemogenetic synaptic
980 silencing of neural circuits localizes a hypothalamus-->midbrain
981 pathway for feeding behavior. *Neuron*, 82, 797-808.
982
- 983 Stuber, G.D., Klanker, M., de Ridder, B., Bowers, M.S., Joosten, R.N.,
984 Feenstra, M.G. & Bonci, A. (2008) Reward-predictive cues enhance
985 excitatory synaptic strength onto midbrain dopamine neurons. *Science*,
986 321, 1690-1692.
987
- 988 Syed, E.C., Grima, L.L., Magill, P.J., Bogacz, R., Brown, P. & Walton, M.E.
989 (2016) Action initiation shapes mesolimbic dopamine encoding of
990 future rewards. *Nature neuroscience*, 19, 34-36.
991
- 992 Szczypka, M.S., Rainey, M.A., Kim, D.S., Alaynick, W.A., Marck, B.T.,
993 Matsumoto, A.M. & Palmiter, R.D. (1999) Feeding behavior in
994 dopamine-deficient mice. *Proceedings of the National Academy of*
995 *Sciences of the United States of America*, 96, 12138-12143.
996
- 997 Tsai, H.C., Zhang, F., Adamantidis, A., Stuber, G.D., Bonci, A., de Lecea, L. &
998 Deisseroth, K. (2009) Phasic firing in dopaminergic neurons is
999 sufficient for behavioral conditioning. *Science*, 324, 1080-1084.
1000
- 1001 Turiault, M., Parnaudeau, S., Milet, A., Parlato, R., Rouzeau, J.D., Lazar, M. &
1002 Tronche, F. (2007) Analysis of dopamine transporter gene expression

1003 pattern -- generation of DAT-iCre transgenic mice. FEBS J, 274, 3568-
1004 3577.
1005
1006 Tye, K.M., Mirzabekov, J.J., Warden, M.R., Ferenczi, E.A., Tsai, H.C.,
1007 Finkelstein, J., Kim, S.Y., Adhikari, A., Thompson, K.R., Andalman,
1008 A.S., Gunaydin, L.A., Witten, I.B. & Deisseroth, K. (2013) Dopamine
1009 neurons modulate neural encoding and expression of depression-
1010 related behaviour. Nature, 493, 537-541.
1011
1012 Ungless, M.A. & Grace, A.A. (2012) Are you or aren't you? Challenges
1013 associated with physiologically identifying dopamine neurons. Trends
1014 Neurosci, 35, 422-430.
1015
1016 Ungless, M.A., Magill, P.J. & Bolam, J.P. (2004) Uniform inhibition of
1017 dopamine neurons in the ventral tegmental area by aversive stimuli.
1018 Science, 303, 2040-2042.
1019
1020 Ungless, M.A., Whistler, J.L., Malenka, R.C. & Bonci, A. (2001) Single
1021 cocaine exposure in vivo induces long-term potentiation in dopamine
1022 neurons. Nature, 411, 583-587.
1023
1024 van der Hoek, G.A. & Cooper, S.J. (1994) The selective dopamine uptake
1025 inhibitor GBR 12909: its effects on the microstructure of feeding in rats.
1026 Pharmacology, biochemistry, and behavior, 48, 135-140.
1027

- 1028 Wang, S., Tan, Y., Zhang, J.E. & Luo, M. (2013) Pharmacogenetic activation
1029 of midbrain dopaminergic neurons induces hyperactivity. *Neuroscience*
1030 *bulletin*, 29, 517-524.
1031
- 1032 Wellman, P., Ho, D., Cepeda-Benito, A., Bellinger, L. & Nation, J. (2002)
1033 Cocaine-induced hypophagia and hyperlocomotion in rats are
1034 attenuated by prazosin. *European journal of pharmacology*, 455, 117-
1035 126.
1036
- 1037 Wise, R.A. (2006) Role of brain dopamine in food reward and reinforcement.
1038 *Philosophical transactions of the Royal Society of London. Series B,*
1039 *Biological sciences*, 361, 1149-1158.
1040
- 1041 Zhou, Q.Y. & Palmiter, R.D. (1995) Dopamine-deficient mice are severely
1042 hypoactive, adipsic, and aphagic. *Cell*, 83, 1197-1209.
1043
1044

1045 **Figure Legends**

1046

1047 **Figure 1: Optogenetic excitation of VTA dopamine neurons selectively**
1048 **decreases intake of high concentration salt jellies during salt appetite.**

1049 A) DATcre⁻ and DATcre⁺ mice were injected with a cre-dependent adeno-
1050 associated virus carrying channelrhodopsin, conjugated to the fluorescent
1051 protein mCherry (AAV-ChR2-mCherry). B) Co-localisation of mCherry and TH
1052 confirmed expression of channelrhodopsin in VTA dopamine neurons in
1053 DATcre⁺ mice. C) Optical stimulation consisted of 8 pulses: 5ms on of a blue
1054 light laser, 37ms off. D) *Ex vivo* whole cell patch recordings confirmed the
1055 optical blue light stimulation protocol was sufficient to depolarise the VTA TH+
1056 positive cells leading to phasic bursts of activity. E) DATcre⁺ (n=4) and
1057 wildtype litter mates (n=3) injected with AAV-ChR2-mCherry in the VTA were
1058 optogenetically stimulated using the same protocol. A significant increase in
1059 the number of dopamine neurons exhibiting cFos expression was observed in
1060 DATcre⁺ mice compared to DATcre⁻ mice (23.1±3.6 vs. 12.9±1.5; t=2.326,
1061 p=0.028; N = 16 & 12 (sections); immunostaining for tyrosine hydroxylase
1062 (TH) and cFos), confirming VTA dopamine neurons were activated *in vivo* by
1063 optical blue light stimulation. F) An acute salt appetite was induced and
1064 assayed by injecting mice with the diuretic furosemide for two days before a
1065 preference test between three jellies of three different NaCl concentrations.
1066 DATcre⁻ and DATcre⁺ mice were optogenetically stimulated with blue light
1067 during the preference test. G) DATcre⁻ (n=8) and H) DATcre⁺ mice (n=6)
1068 differed in their intake of the different concentration salt jellies, Time x
1069 Genotype x Concentration F(4, 48)=3.6 p<.05. Main effects of Time

1070 $F(2,24)=10.3$ $p<0.005$, Concentration $F(1.5,18.2)=9.4$ $p<.005$ and Time x
 1071 Concentration $F(2.5,30.4)=18.4$ $p<0.001$) were also revealed with statistical
 1072 analysis. There was no significant interaction of Time x Genotype
 1073 ($F(2,24)=1.7$ $p>0.1$ N.S. I) A selective reduction in intake of the high
 1074 concentration salt jelly occurred during the first 10 min of the test session in
 1075 the DATcre+ mice, Concentration x Genotype $F(2,24)=7.1$ $p<.005$,
 1076 Concentration $F(1.5, 17.6)=34.11$ $p<.001$), pairwise comparisons 0.3M salt
 1077 DATcre- vs DATcre+ $p<.05$. J) and K) When tested a week later in the
 1078 absence of stimulation, mice preferentially consumed the highest
 1079 concentration salt jelly (Concentration $F(1.3, 16.1)=40.6$ $p<.001$). Overall mice
 1080 decreased their consumption across time ($F(1.7,20.0)=56.4$ $p<.001$)
 1081 presumably due to satiation which resulted in an overall change in preference
 1082 for the high concentration salt jelly (Time x Concentration $F(2.5,16.4)$ $p<.001$).
 1083 No differences in intake were observed between salt-depleted groups across
 1084 the session (Time x Genotype x Concentration $F(4,48)= 1.7$ $p>0.1$ N.S.,
 1085 Concentration x Genotype, Time x Genotype and Genotype all F 's <1 $p>0.5$
 1086 N.S), L) nor during the first 10 min of the session (Genotype, Concentration x
 1087 Genotype all F 's <1 , p 's >0.3). M) DATcre- ($n=9$) and DATcre+ ($n=6$) mice
 1088 injected with the cre dependent AAV-ChR2-mcherry virus in the VTA and
 1089 were tested using an biased CPP test. Preference was assessed for one of
 1090 two chambers (pre-test) followed by optogenetic stimulation for two days in
 1091 the non-preferred chamber (days 2 and 4) and two days of no stimulation in
 1092 the preferred chamber (days 3 and 5). The last day (post-test) mice were
 1093 tested for their preference in the absence of stimulation. N) DATcre- mice
 1094 ($n=6$) showed no preference for the chamber where they had previously

received stimulation (Stimulation $F(1,5)=2.9$ $p>0.1$ N.S.; Session $F(1,5)=2.6$ $p>0.1$ N.S.; Session x Stimulation $F<1$ $p>0.7$ N.S.). O) DATcre+ mice ($n=9$) showed a significant preference for the chamber in which they had previously received stimulation (Session x Stimulation $F(1,8)=7.0$ $p<0.05$), pairwise comparisons revealed this was specific to the stimulated chamber (pre vs post session $p<0.01$). P) Optogenetic stimulation did not change locomotor activity as measured during the stimulation days of the unbiased CPP test (Stimulation; Stimulation x Genotype; Genotype all $F's<1$ $p's>0.4$ N.S.).

Figure 2: Chemogenetic inhibition of VTA dopamine neurons does not affect intake of high concentration salt jellies during salt appetite. A) DATcre+ mice ($n=9$) and DATcre- mice ($n=11$) were injected in the VTA with cre-dependent adeno-associated virus carrying the Gi-coupled human M4 muscarinic DREADD coding sequence conjugated to the fluorescent protein mCherry (AAV-hM4Di-mCherry). B) Co-localisation of mCherry and TH staining confirmed expression of AAV-hM4Di-mCherry in VTA dopamine neurons of DATcre+ mice. C) *Ex vivo* recordings confirmed CNO application to coronal VTA slices resulted in hyperpolarisation of VTA TH+ve neurons in DATcre+ mice that had been previously injected with AAV-hM4Di-mCherry. D) and E) Systemic CNO activation of AAV-hM4Di-mCherry prior to the salt appetite assay resulted in no significant effects on intake between genotypes (Time x Concentration x Genotype, Concentration x Genotype, Time x Genotype all $F's<1$ all $p's>0.5$). Intake decreased over time ($F(1.3,23.9)=100.3$ $p<0.001$) with preference in concentration also changing over time ($F(1.9,33.8)=6.0$ $p<0.001$). F) Systemic CNO activation of AAV-

1120 hM4Di-mCherry in the VTA of DATcre⁺ (n=10) and DATcre⁻ (n=12) mice
 1121 resulted in a significant reduction in locomotor activity in DATcre⁺ mice,
 1122 Treatment x Genotype $F(1,18)=8.5$ $p<.01$ pairwise comparisons revealed
 1123 significant effects only following CNO treatment, DATcre⁺ vs DATcre⁻ $p<.005$.
 1124 There was a significant interaction between treatment and time, with
 1125 locomotor activity continuing to reduce with time in the CNO DATcre⁺ group
 1126 (Time x Treatment $F(11,198)=2.8$ $P<.005$). However, this did not differ
 1127 between genotypes (Time x Treatment x Genotype $F(11,198)=1.1$ $p>0.3$;
 1128 Time x Genotype $F<1$ $p>0.7$). Data represented as means \pm SEM.

1129
 1130 **Figure 3: Chemogenetic excitation of VTA dopamine neurons induces**
 1131 **behavioural hyperactivity and non-selective reduction in salt intake.** A)
 1132 DATcre⁺ mice and DATcre⁻ mice were injected with cre-dependent adeno-
 1133 associated virus carrying the Gq-coupled human M3 muscarinic DREADD
 1134 coding sequence conjugated to the fluorescent protein mCherry (AAV-
 1135 hM3Dq-mCherry). B) Co-localisation of mCherry and TH staining confirmed
 1136 expression of AAV-hM4Di-mCherry in VTA dopamine neurons of DATcre⁺
 1137 mice. C) *Ex vivo* recordings confirmed CNO application to coronal VTA slices
 1138 resulted in depolarisation of VTA TH+ve neurons in DATcre⁺ mice that had
 1139 been previously injected with AAV-hM3Dq-mCherry. D) and E) Systemic CNO
 1140 activation of AAV-hM4Di-mCherry prior to the salt appetite assay resulted in a
 1141 significant reduction in intake across the session of DATcre⁺ mice (n=11)
 1142 compared to DATcre⁻ mice (n=12), Genotype x Time $F(2,42)= 5.7$ $p<.01$.
 1143 Overall, intake decreased with time ($F(2,42)=140.8$ $p<.001$) and DATcre⁺
 1144 differ in intake to DATcre⁻ ($F(1,21)=16.5$ $p<.005$). Unlike optogenetic

1145 excitation of VTA dopamine neurons, this difference in intake between
 1146 DATcre+ and DATcre- mice was not due to changes in preference of
 1147 concentration (Time x Concentration x Genotype $F<1$ $p>0.5$ N.S.,
 1148 Concentration x Genotype $F(2,42)=2.1$ $p>0.1$ N.S., Concentration
 1149 $F(1.6,34.5)=27.5$ $p<.001$). Changes in preference of salt jelly changed overall
 1150 over the course of the session regardless of the genotype of the mouse (Time
 1151 x Concentration $F(3.1,64.4)=10.4$ $p<.001$). Significant differences in intake
 1152 occurred primarily in the first and last thirds of the session, pairwise
 1153 comparisons; p 's $<.005$ for intake during both 0-10 min and 20-30 min of the
 1154 session for DATcre+ vs DATcre-. F) DATcre+ (n=15) and DATcre- mice
 1155 (n=12) infused with the same hM3Dq virus in the VTA and injected
 1156 systemically with the same dose of CNO, significantly increased in locomotor
 1157 behaviour confirming the activation of the virus and effectiveness of the CNO
 1158 dose Genotype x Drug $F(1,23)=46.2$ $p<.001$, Drug $F(1,23)=23.5$ $p<.001$;
 1159 Genotype $F(1,23)=71.1$ $p<.001$. Data represented as means \pm SEM.

1160

1161 **Figure 4: Optogenetic excitation of VTA dopamine neurons selectively**
 1162 **decreases intake of high concentration sucrose jellies following an**
 1163 **overnight fast.** A+B) Optogenetic excitation of VTA dopamine neurons
 1164 resulted in a selective decrease in consumption of the high concentration
 1165 sucrose jelly in B) DATcre+ mice (n=8) with respect to A) DATcre- mice
 1166 (n=15), Time x Concentration x Genotype $F(4,84)=5.2$ $p<.005$, Concentration
 1167 x Genotype $F(2,42)=3.6$ $p<.05$. There was no overall preference for one
 1168 concentration ($F(2,42)=1.6$ $p>0.2$), nor did a preference occur over time (Time
 1169 x Concentration $F<1$ $p>0.5$), or overall intake differ between mice (Time x

1170 Genotype, $F < 1$, $p > 0.5$; Genotype $F < 1$, $p > 0.4$). The selective reduction in
 1171 intake of the highest concentration sucrose jelly in DATcre+ ($n=8$) mice with
 1172 respect to DATcre- ($n=16$) mice was specific to the first 10 min of the session,
 1173 Concentration \times Genotype $F(2,44)=5.3$ $p < .01$, pairwise comparisons 30%
 1174 sucrose DATcre- vs DATcre+ $p < .01$.

1175

1176 **Figure 5: Salt appetite and sucrose appetite do not affect firing activity**
 1177 **or excitatory synaptic strength in putative VTA dopamine neurons. A)**

1178 Traces of firing activity from putative dopamine neurons from C57BL6 mice
 1179 either salt-depleted or non-depleted saline controls. B) No differences in firing
 1180 frequency of putative dopamine neurons were seen following salt depletion
 1181 ($n=22(13)$) with respect to control saline injected controls ($n=18(9)$) ($U=135$
 1182 $p > 0.5$ N.S.). No differences in % spikes in bursts between groups ($U=148$
 1183 $p > 0.1$ N.S.). The coefficient of variation of the interspike interval did not differ
 1184 between groups ($U=186$ $p > 0.7$ N.S.). C) Individual frequency of firing of each
 1185 putative dopamine neuron against its % spikes in a burst. D) Traces of firing
 1186 activity from putative VTA dopamine neurons from C57BLk6 mice either
 1187 fasted or non-fasted controls. E) No differences in firing frequency of putative
 1188 dopamine neurons were seen following fasting ($n=27(10)$) with respect to
 1189 controls ($n=22(10)$) ($U=246$ $p > 0.3$ N.S.). No differences in % spikes in bursts
 1190 between groups ($U=209$ $p > 0.8$ N.S.). The coefficient of variation of the
 1191 interspike interval did not differ between groups ($U=265$, $p > 0.5$ N.S.). F)
 1192 Individual frequency of firing of each putative dopamine neuron against its %
 1193 spikes in a burst. G) Example traces of excitatory postsynaptic potentials in
 1194 putative dopamine neurons from salt-depleted and non-depleted mice. H)

1195 AMPA/NMDA ratio was unaffected in dopamine neurons of salt-depleted
1196 (n=10(5)) vs non-depleted mice (n=9(4)) (U=34 $p>0.1$ N.S.). I) Example traces
1197 of excitatory postsynaptic potentials in putative dopamine neurons from fasted
1198 and non-fasted mice. J) AMPAR/NMDAR ratio was unaffected in putative
1199 dopamine neurons of fasted (n=10(5)) vs non-fasted mice (n=11(6)) (U=50
1200 $p>0.1$ N.S.) Ns are cells (animals).

1201

1202 **Figure 6: Optogenetic excitation of VTA dopamine neurons does not**
1203 **disrupt salt concentration preference following an overnight fast. A+B)**

1204 Although optogenetic excitation of VTA dopamine neurons reduced overall
1205 intake in the DATcre+ (n=16) compared to DATcre- mice (n=14) following an
1206 overnight fast throughout the session, it did not affect salt concentration
1207 preference. Time x Genotype x Concentration $F(4,112) = 1.1$ $p>0.3$ N.S.
1208 Overall intake was significantly reduced in DATcre+ mice (Genotype
1209 $F(1,28)=25.9$ $p<.001$) which differed across time, Time x Genotype $F(2, 56) =$
1210 3.6 $p<.05$. C) DATcre+ and DATcre- mice preferentially consumed the low
1211 concentration salt +10% sucrose jelly, Concentration $F(1.7, 48.8)=21.3$
1212 $p<.005$ (pw comparisons-, intake was significantly different between all
1213 concentrations $p's<.05$), which did not differ between genotypes,
1214 Concentration x Genotype $F<1$ $p>0.5$. Preference changed with time (Time x
1215 Concentration $F(2.4, 68.2)=10.3$ $p<.001$). D) Concentration preference did not
1216 differ between DATcre+ and DATcre- mice (Concentration x Genotype $F<1$
1217 $P>0.5$) with all mice preferring the low salt concentration jelly (Concentration
1218 $F(1.9,45.6)=21.0$ $p<0.001$). Data represented as means \pm SEM.











